| 发明名称 | Kanamycin antisense nucleic acid for the treatment of cancer | ||
| 摘要 | The invention relates to a nucleic acid comprising a sequence complementary to a fragment of the sequence coding for the kanamycin resistance protein. This nucleic acid is useful as a DNA vaccine adjuvant, and can be used e.g. for treating cancer, for example in combination with a non-immunosuppressive inducer of tumor cell apoptosis such as all-trans retinoic acid (ATRA). | ||
| 申请公布号 | US9029135(B2) | 申请公布日期 | 2015.05.12 |
| 申请号 | US201013258173 | 申请日期 | 2010.03.26 |
| 申请人 | Institut National de la Sante et de la Recherche Medicale (Inserm);Universite Paris Diderot-Paris 7 | 发明人 | Padua Rose Ann;Chomienne Christine |
| 分类号 | C12N15/00;C12N15/11;A01N31/04;A61K39/39;C12N15/113;A61K39/00 | 主分类号 | C12N15/00 |
| 代理机构 | McDermott Will & Emery LLP | 代理人 | McDermott Will & Emery LLP |
| 主权项 | 1. An isolated nucleic acid comprising: an antisense sequence consisting of a sequence complementary to a fragment of a sequence coding for a kanamycin resistance protein; and a sequence which encodes an immunogenic polypeptide; wherein the fragment is at least 100 nucleotides and at most 500 nucleotides in length; wherein the antisense sequence encodes at least one immunogenic polypeptide selected from the group consisting of a polypeptide of sequence SEQ ID NO: 18 and a polypeptide of sequence SEQ ID NO: 19; wherein the sequence coding for the kanamycin resistance protein has a sequence consisting of nucleotides 1226 to 2020 of SEQ ID NO: 9; and wherein said antisense sequence is under control of a mammalian promoter allowing its transcription. | ||
| 地址 | Paris FR | ||